Given the variety of immuno-oncology treatments currently in use for therapies in patients with different cancer types, including melanoma, NSCLC, CRC, and HCC [97,108], novel research examining the relationship between the expression of the POLD1 protein and the clinical outcomes in patients receiving immunotherapy would be of great importance. This evidence concerns the gene POLD1 and colorectal carcinoma.